American Association for Cancer Research
00085472can153243-sup-158812_1_supp_3527056_f87kfz.png (302.49 kB)

Suppl Fig. 1 from Inhibiting Mitochondrial DNA Ligase IIIα Activates Caspase 1–Dependent Apoptosis in Cancer Cells

Download (302.49 kB)
posted on 2023-03-31, 00:22 authored by Annahita Sallmyr, Yoshihiro Matsumoto, Vera Roginskaya, Bennett Van Houten, Alan E. Tomkinson

Characterization of HeLa Rho minus cells. Panel A. Amplification of specific fragments and nuclear and mitochondrial DNA using the polymerase chain reaction showing the absence of mitochondrial DNA in HeLa Rho minus cells. Panel B. Immunofluorescence of HeLa and HeLa Rho minus stained with Mitotracker Red. Panel C. Effect of L67 on the proliferation of HeLa and HeLa Rho minus cells grown in media containing pyruvate and uridine.



University of New Mexico


Department of Health, PA



Elevated levels of DNA ligase IIIα (LigIIIα) have been identified as a biomarker of an alteration in DNA repair in cancer cells that confers hypersensitivity to a LigIIIα inhibitor, L67, in combination with a poly (ADP-ribose) polymerase inhibitor. Because LigIIIα functions in the nucleus and mitochondria, we examined the effect of L67 on these organelles. Here, we show that, although the DNA ligase inhibitor selectively targets mitochondria, cancer and nonmalignant cells respond differently to disruption of mitochondrial DNA metabolism. Inhibition of mitochondrial LigIIIα in cancer cells resulted in abnormal mitochondrial morphology, reduced levels of mitochondrial DNA, and increased levels of mitochondrially generated reactive oxygen species that caused nuclear DNA damage. In contrast, these effects did not occur in nonmalignant cells. Furthermore, inhibition of mitochondrial LigIIIα activated a caspase 1–dependent apoptotic pathway, which is known to be part of inflammatory responses induced by pathogenic microorganisms in cancer, but not nonmalignant cells. These results demonstrate that the disruption of mitochondrial DNA metabolism elicits different responses in nonmalignant and cancer cells and suggests that the abnormal response in cancer cells may be exploited in the development of novel therapeutic strategies that selectively target cancer cells. Cancer Res; 76(18); 5431–41. ©2016 AACR.